跳至主要内容
临床试验/jRCT1061260022
jRCT1061260022尚未招募不适用

A prospective comparative study evaluating the efficacy and safety of Juzentaihoto in patients with non-muscle invasive bladder cancer receiving intravesical Bacillus Calmette-Guerin therapy

未提供0 个研究点目标入组 60 人开始时间: 待定
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non Randomized

入排标准

年龄范围
18age old over 至 No limit(—)
性别
All

入选标准

  • Patients who underwent transurethral resection of bladder tumor (TURBT) at our institution.
  • Patients histologically diagnosed with T1 disease or carcinoma in situ (CIS).
  • Patients who provided consent to be prescribed and take Juzentaihoto.

排除标准

  • Patients who refused to provide consent for participation in this study.
  • Patients who received other Kampo medicines within 2 weeks before the initiation of intravesical Bacillus Calmette-Guerin (BCG) therapy.
  • Patients who are unable to take oral medications.
  • Patients with a known allergy to Kampo medicines.

研究者

发起方
未提供

相似试验